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the Impact of Cardiac Risk Factor Management*Hans Kottkamp, MDSEE PAGE 2222C atheter ablation of atrial ﬁbrillation (AF)has undergone considerable developmentwithin the last 15 years. Originally, the pro-
cedure was predominantly reserved for relatively
young patients with no signiﬁcant structural heart
disease. Subsequently, more elderly patients and pa-
tients with signiﬁcant structural heart disease and
substantial numbers of cardiac risk factors have
been treated with catheter ablation. For example,
within the last 10 years, the mean age of patients un-
dergoing AF ablation in our laboratory increased from
54 to 67 years. Recommendations for patient selec-
tion, procedural techniques, patient management,
and follow-up were recently updated in the expert
consensus statement (1).
In addition to further reductions in the complica-
tion rate, another major target for improving this
relatively invasive catheter procedure is reduction of
the necessity for redoing procedures. In the young
and otherwise healthy patient population undergoing
AF ablation, the typical reason for arrhythmia re-
currences (although not always) is reconnection of
the initially isolated pulmonary veins. With inclusion
of patients who have signiﬁcant structural heart dis-
ease and substantial numbers of cardiac risk factors,
this scenario is more complex and combined with our
still-limited understanding of AF pathophysiology.
Besides the well-accepted role of pulmonary vein foci
in triggering the arrhythmia, the nature of the sub-
strate maintaining AF is still under debate and was*Editorials published in the Journal of the American College of Cardiology
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consultant for and shareholder of Kardium.recently called the “unknown species” in an editorial
(2). Within the last decade, data on the relationship
between AF and obesity, obstructive sleep apnea
(OSA), alcohol consumption, and cardiometabolic
risk factors have emerged (3–6). Furthermore, in a
recently published randomized clinical study (7),
weight reduction plus intensive general risk factor
management (RFM) resulted in reduced AF symp-
tom burden and severity. AF also has a genetic
component, and a primary ﬁbrotic atrial cardiomy-
opathy was described as a speciﬁc disease supplying
substrates for AF, atrial tachycardia, sinus node
disease, AV node disease, and thromboembolic
complications (8,9).In this issue of the Journal, Pathak et al. (10) report
the results of the ARREST-AF Cohort Study (Aggres-
sive Risk Factor Reduction Study for Atrial Fibrilla-
tion) and their implications for catheter ablation
outcomes. This study comprised consecutive patients
with body mass index $27 kg/m2 and $1 risk factor
(hypertension, glucose intolerance/diabetes mellitus,
hyperlipidemia, OSA, smoking, or alcohol excess)
undergoing catheter ablation for symptomatic AF,
despite use of antiarrhythmic drugs. Patients in the
RFM group (n ¼ 61) attended an intensive physician-
directed program in a RFM clinic, according to
American College of Cardiology/American Heart
Association guidelines (11). The control group sub-
jects (n ¼ 88) continued RFM under the direction of
their treating physician. RFM resulted in signiﬁcantly
greater weight and blood pressure reductions, and
better glycemic control and lipid proﬁles. Reviews
were every 3 months for the ﬁrst year and then every
6 months thereafter, including ambulatory 7-day
monitoring at each review. At follow-up after catheter
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2233ablation, arrhythmia-free survival after single and
multiple procedures was signiﬁcantly greater in RFM
patients compared with control subjects. On multi-
variate analysis, RFM was an independent predictor
of arrhythmia-free survival, with an impressive haz-
ard ratio of 4.8 (10).
This report from Pathak et al. (10) conﬁrms
and extends the growing body of evidence that
a variety of cardiac risk factors affect procedural
outcomes in patients with AF undergoing catheter
ablation (12–15). The “aggressive” RFM used in the
study by Pathak et al. was, indeed, impressive and
comprehensive, including blood pressure control,
weight management, lipid management, glycemic
control, sleep-disordered breathing management,
smoking cessation framework, and alcohol reduction.
Furthermore, the improvement in long-term success
of AF ablation was signiﬁcant and seems substantial,
even given the limitation that the study was
nonrandomized.
It is also impressive that of 281 consecutive pa-
tients referred for catheter ablation of symptomatic
AF, 165 had a body mass index $27 kg/m2 plus $1
risk factor. In other words, almost 60% of the pa-
tients referred for catheter ablation of symptomatic
AF qualiﬁed for RFM because of obesity plus addi-
tional risk factors. This ﬁnding conﬁrms recent es-
timations that almost 70% of U.S. adults are either
overweight or obese, with w35% being obese (16).
The clinical implications of the data presented
by Pathak et al. (10) seem clear and important. First,
“aggressive” RFM in patients with obesity and other
cardiac risk factors substantially improved outcomes
after catheter ablation of AF. Second, given the
biomedical and socioeconomic consequences of ob-
esity on morbidity and mortality, the high preva-
lence of obesity needs to be generally addressed
with a higher social priority.
The scientiﬁc implications with respect to the hu-
man AF substrate, or the pathophysiology of AF in
general, seem less clear. In this study (10), because a
comprehensive RFM was performed, the relative
contribution of each risk factor cannot be assessed. In
addition, even the single risk factor, obesity, can
promote AF from different directions. For incident
AF, analysis demonstrated that left atrial enlarge-
ment was one critical mediating factor for obesity (3).
Furthermore, increased systemic inﬂammation
marker levels (17), changes in neurohumoral activa-
tion (18), increased arterial stiffness (19), and in-
creased OSA incidence (5), indicate that the
interaction of obesity with different aspects of AF
pathophysiology is complex. Conversely, the vastmajority of overweight and obese patients do not
have AF. Therefore, it may be argued that rather than
acting as a primary “substrate maker,” obesity mod-
ulates or promotes AF. Atrial ﬁbrosis seems the
common endpoint of atrial structural remodeling,
forming the substrate for AF maintenance. But where
does this ﬁbrosis come from? Originally, aging and
general cardiac disease, as well as the arrhythmia it-
self, were assumed to underlie the structural remod-
eling process leading to the progression of AF from
paroxysmal to persistent forms. However, an autopsy
study in which no correlation could be detected be-
tween patient age and increased extent of ﬁbrosis
(20) called the importance of age itself into question.
Results from analysis of intraoperatively obtained
specimens, autopsy ﬁndings, electroanatomic map-
ping studies, and magnetic resonance imaging in-
vestigations showed high variability in the extent of
ﬁbrosis, with some patients with paroxysmal AF
having massive ﬁbrosis (even very early after the ﬁrst
AF episode) and some patients with persistent AF
showing mild ﬁbrosis, with recent analyses suggest-
ing a speciﬁc underlying structural atrial disease,
ﬁbrotic atrial cardiomyopathy (8,9). In contrast, little
clinical evidence was found that AF itself signiﬁcantly
produces ﬁbrosis, in the sense of “AF begets AF” (9).
In a surgical scenario, pre-operatively elevated serum
markers of collagen synthesis were recently reported
to be associated with post-surgical AF in patients with
no history of AF (21). Importantly, pre-existing left
atrial ﬁbrosis was signiﬁcantly higher in patients who
developed post-surgical AF, compared with those
who stayed in sinus rhythm, suggesting modulating
effects of cardiac surgery on pre-existing and, thus
far, subclinical left atrial ﬁbrosis/ﬁbrotic atrial
cardiomyopathy.
In summary, the authors (10) are to be commended
for rigorously applying “aggressive” RFM and dem-
onstrating its beneﬁcial effects on long-term success
after catheter ablation of AF. Their study sheds
further light on the substantial clinical role of modi-
ﬁable factors, such as obesity and other cardiac risk
factors, and has signiﬁcant clinical implications.
Certainly the “unknown species” human AF sub-
strate as well as the speciﬁc roles of promoters/
modulators of AF pathophysiology (e.g., cardiac
risk factors, inﬂammation, surgery, cancer) deserve
further evaluation.
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